Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer

Fig. 4

Sensitivity of lung cancer types to drug candidates. A Volcano plot for each lung cancer type. BP-value bar plot of gene set enrichment analysis of transcriptome signatures for three drugs acquired from machine learning. C Five genes were associated with the cell cycle pathway. PDC gene expression heatmap for five genes detected in machine-learning feature importance and “CYCLIN A/B1/B2 ASSOCIATED EVENTS” pathway, and normalized AZD7762 AUCs. D Scatter plots for AZD7762 AUC and FOXM1 expression for PDCs and cell lines. EFOXM1 expression comparison among four lung cancer cohorts between SCLC and LUAD. P-values were determined using the Wilcoxon rank-sum test between SCLC and LUAD. F Protein levels of FOXM1 and β-actin in siRNA-transfected H69 cells analyzed using western blotting. Ctrl represents the control, and siFOXM1-#6 and siFOXM1-#7 are FOXM1 siRNAs. G Cell cycle phase assessment according to control and FOXM1 siRNA conditions of H69 cells. After incubation, the cells were analyzed using flow cytometry to evaluate the DNA content. Representative DNA content profiles from three independent experiments are shown. Bar plots present the proportions of cells in cell cycle phases (upper panel) and cell counts (y-axis) based on propidium iodide (PI) staining (x-axis; lower panel). H Drug response curves for testing AZD7762 sensitivity in control siRNA (Ctrl) and siRNA #6- and #7-transfected H69 cells. The half-maximal inhibitory concentration (IC50) of AZD7762 siRNA-transfected cells is shown in the panel. All experiments were performed in quadruplicate. The values represent the mean ± SEM (Student’s t-test, *P < 0.05; ***P < 0.001)

Back to article page